737 related articles for article (PubMed ID: 31782077)
1. Amyloidosis in Heart Failure.
Ihne S; Morbach C; Obici L; Palladini G; Störk S
Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
Smiley DA; Rodriguez CM; Maurer MS
Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
[TBL] [Abstract][Full Text] [Related]
4. Updates in Cardiac Amyloidosis Diagnosis and Treatment.
Stern LK; Kittleson MM
Curr Oncol Rep; 2021 Mar; 23(4):47. PubMed ID: 33725199
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Care of Patients with Cardiac Amyloidosis.
Itzhaki Ben Zadok O; Kornowski R
Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
[TBL] [Abstract][Full Text] [Related]
6. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
Perlini S; Mussinelli R; Salinaro F
Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
[TBL] [Abstract][Full Text] [Related]
7. Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
Manolis AS; Manolis AA; Manolis TA; Melita H
Eur J Intern Med; 2019 Sep; 67():1-13. PubMed ID: 31375251
[TBL] [Abstract][Full Text] [Related]
8. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
Fine NM; Davis MK; Anderson K; Delgado DH; Giraldeau G; Kitchlu A; Massie R; Narayan J; Swiggum E; Venner CP; Ducharme A; Galant NJ; Hahn C; Howlett JG; Mielniczuk L; Parent MC; Reece D; Royal V; Toma M; Virani SA; Zieroth S
Can J Cardiol; 2020 Mar; 36(3):322-334. PubMed ID: 32145862
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
Yamamoto H; Yokochi T
ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
[TBL] [Abstract][Full Text] [Related]
10. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis.
Kreusser MM; Volz MJ; Knop B; Ehlermann P; Schmack B; Ruhparwar A; Hegenbart U; Schönland SO; Katus HA; Raake PW
Clin Res Cardiol; 2020 Jun; 109(6):700-713. PubMed ID: 31630214
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Amyloidosis Treatment.
Stern LK; Patel J
Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
[TBL] [Abstract][Full Text] [Related]
12. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
13. [Cardiac amyloidosis - important differential diagnosis in heart failure].
Morbach C; Steinhardt M; Störk S
Dtsch Med Wochenschr; 2022 Nov; 147(23):1522-1530. PubMed ID: 36384153
[TBL] [Abstract][Full Text] [Related]
14. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Gertz MA; Dispenzieri A
JAMA; 2020 Jul; 324(1):79-89. PubMed ID: 32633805
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
[TBL] [Abstract][Full Text] [Related]
16. [Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)].
Tereshchenko SN; Zhirov IV; Moiseeva OM; Adasheva TV; Ansheles AA; Barbarash OL; Galyavich AS; Gudkova AI; Zateyshchikov DA; Kostareva AA; Nasonova SN; Nedogoda SV; Pecherina TB; Ryzhkova DV; Sergienko VB
Ter Arkh; 2022 May; 94(4):584-595. PubMed ID: 36286812
[TBL] [Abstract][Full Text] [Related]
17. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.
Hänselmann A; Berliner D; Bauersachs J; Bavendiek U
Herz; 2022 Aug; 47(4):324-331. PubMed ID: 35674775
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin cardiac amyloidosis.
Porcari A; Fontana M; Gillmore JD
Cardiovasc Res; 2023 Feb; 118(18):3517-3535. PubMed ID: 35929637
[TBL] [Abstract][Full Text] [Related]
19. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Griffin JM; Maurer MS
Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
[TBL] [Abstract][Full Text] [Related]
20. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.
López-Sainz Á; Hernandez-Hernandez A; Gonzalez-Lopez E; Domínguez F; Restrepo-Cordoba MA; Cobo-Marcos M; Gómez-Bueno M; Hernandez-Perez FJ; Oteo JF; Mirelis JG; Cavero MA; Moñivas V; Mingo Santos S; de Haro-Del Moral FJ; Krsnik I; Salas C; Bornstein B; Briceño A; López JA; Vázquez J; Alonso-Pulpón L; Segovia J; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2021 Feb; 74(2):149-158. PubMed ID: 32317158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
